BIO-Europe Spring 2026 – Meet Us there! We’re pleased to share that Dr. Gregory Penner will be participating in BIO-Europe Spring 2026, during March 23-25 in Lisbon, Portugal. Would you like to learn more about our…
Advanced Proteomics Masterclass: Techniques and Applications in Precision Medicine The masterclass event aims to introduce and explore APTAMARKER. The APTAMARKER platform is an advanced aptamer-based technology platform developed by Dr. Gregory Penner and his team…
Join us at BIO-Europe Fall 2025 We’re pleased to share that Dr. Gregory Penner, Chief Scientific Officer at NeoVentures Biotechnology Europe, will be participating in BIO-Europe Fall 2025. The event will be taking place November 3-5…
NeoVentures Biotechnology Europe Partners with Ombion Biomarker discovery has driven major advances in healthcare, but most traditional approaches rely on animal-produced antibodies. Researchers generate these antibodies by introducing human recombinant proteins into animals and harvesting…
NeoVentures Biotechnology Europe has joined NVIDIA Inception, a program designed to help startups evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA. At NVB Europe, we’ve developed the Aptamarker Platform,…
NeoVentures Biotechnology Europe and IRD-Montpellier Launch Strategic Partnership in Single-Cell Proteomics The Institut de Recherche pour le Développement, Délégation Régionale Occitanie (IRD-Montpellier), and NeoVentures Biotechnology Europe (NVBE) are proud to announce a strategic partnership to…
NeoVentures Biotechnology Europe will be attending BIO-Europe Spring.
First Human Test Application of the Aptamarker Platform The first human test of the Aptamarker Platform demonstrated its ability to screen plasma for all possible biomarkers simultaneously. This milestone was highlighted in the study “Aptamarker…
NeoNeuro Receives Investment from ADDF NeoNeuro announced today that the Alzheimer’s Drug Discovery Foundation (ADDF) invested in the company through its Diagnostics Accelerator. The initiative aims to fast-track development of novel biomarkers for early detection…
Blood Based Diagnostics of Alzheimer’s Disease. Early detection of Alzheimer’s disease (AD) relies on identifying reliable biomarkers in blood. In our study, we focused on the methods of biomarker discovery rather than the biomarkers themselves.…
